Latest filings (excl ownership)
15-12B
Securities registration termination
27 Jan 22
6-K
Current report (foreign)
8 Oct 21
25
Voluntary exchange delisting
20 Sep 21
F-X
Appointment of agent for service of process by issuers registering securities
15 Sep 21
6-K
TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares
8 Sep 21
6-K
2021 Annual General Meeting Minutes
26 Aug 21
6-K
TLC Reports Second Quarter 2021 Financial Results
12 Aug 21
F-X
Appointment of agent for service of process by issuers registering securities
5 Aug 21
6-K
Notice of the First Extraordinary General Meeting of 2021
4 Aug 21
6-K
Current report (foreign)
22 Jul 21
6-K
Current report (foreign)
8 Jul 21
6-K
Current report (foreign)
7 Jul 21
6-K
TLC Announces Details of Stock Swap Transactions
6 Jul 21
6-K
Notice of 2021 Annual General Meeting
28 May 21
6-K
TLC Reports First Quarter 2021 Financial Results
14 May 21
20-F
2020 FY
Annual report (foreign)
30 Mar 21
6-K
TLC Reports Fiscal Year End 2020 Financial Results
5 Feb 21
6-K
Current report (foreign)
4 Jan 21
6-K
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain
28 Dec 20
6-K
TLC Reports Third Quarter 2020 Financial Results
28 Oct 20
6-K
6-K for TLC-19 Patient
14 Oct 20
6-K
TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19
7 Oct 20
6-K
Current report (foreign)
31 Aug 20
6-K
TLC and 3SBio Announce Acceptance of Marketing
26 Aug 20
6-K
Current report (foreign)
18 Aug 20
6-K
TLC Reports Second Quarter 2020 Financial Results
5 Aug 20
6-K
Current report (foreign)
24 Jun 20
6-K
2020 Annual General Meeting Minutes
15 Jun 20
6-K
TLC Reports First Quarter 2020 Financial Results
13 May 20
6-K
Notice of the 2020 Annual General Meeting
4 May 20
20-F
2019 FY
Annual report (foreign)
10 Mar 20
6-K
Meeting Minutes for the First Extraordinary General Meeting of
18 Feb 20
6-K
TLC Reports Fiscal Year End 2019 Financial Results
11 Feb 20
6-K
Notice of the First Extraordinary General Meeting of 2020
7 Feb 20
6-K
Current report (foreign)
6 Dec 19
6-K
TLC Announces Completion of US$27 Million Financing
25 Oct 19
6-K
TLC Reports Third Quarter 2019 Financial Results
22 Oct 19
6-K
TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain
1 Oct 19
6-K
TLC Reports Second Quarter 2019 Financial Results and Provides Business Update
30 Jul 19
6-K
Current report (foreign)
4 Jun 19
Latest ownership filings
SC 13D/A
Lin Chang-Hai
8 Mar 22
SC 13D/A
Lin Chang-Hai
18 Feb 22
SC 13D/A
Lin Chang-Hai
10 Jan 22
SC 13D/A
Lin Chang-Hai
12 Nov 21
SC 13D/A
Lin Chang-Hai
20 Oct 21
SC 13D/A
Lin Chang-Hai
20 Aug 21
SC 13D
Lin Chang-Hai
15 Jul 21
SC 13G
Karst Peak Capital Ltd
16 Feb 21
SC 13G/A
Lin Chang-Hai
12 Feb 21
SC 13D/A
BURRILL LIFE SCIENCES CAPITAL FUND III L P
19 Jun 20
SC 13G
Lin Chang-Hai
19 Jun 20
SC 13D
Taiwan Liposome Company, Ltd.
19 Feb 19
SC 13G
Taiwan Liposome Company, Ltd.
14 Feb 19